Nykode Therapeutics is a leading clinical-stage biopharmaceutical company. With our intelligent modular platform and tailored hyper-targeting, we’re unlocking unlimited possibilities for the future of medicine.
With our unique and innovative modular vaccine technology, we’re specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting immune responses.
2007
Served areaWorldwide
HeadquartersGaustadalléen 21, 0349 Oslo – Norway
294,694,309
IPOOct. 7, 2020
Stock exchange(s)Euronext Oslo